Analysts Issue Forecasts for GH Research FY2026 Earnings

GH Research PLC (NASDAQ:GHRSFree Report) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for GH Research in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($1.72) for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GH Research (NASDAQ:GHRSGet Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.42.

GHRS has been the subject of several other research reports. Royal Bank of Canada started coverage on GH Research in a research report on Friday, March 7th. They issued an “outperform” rating and a $31.00 price target for the company. Stifel Nicolaus boosted their target price on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Guggenheim dropped their target price on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, GH Research presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Read Our Latest Research Report on GHRS

GH Research Trading Up 7.4%

GHRS opened at $13.79 on Tuesday. The firm has a market cap of $717.47 million, a P/E ratio of -17.46 and a beta of 0.97. GH Research has a 12 month low of $6.00 and a 12 month high of $20.50. The stock has a 50-day moving average of $10.59 and a 200 day moving average of $10.33.

Institutional Trading of GH Research

Several institutional investors have recently added to or reduced their stakes in GHRS. Cormorant Asset Management LP boosted its position in GH Research by 238.8% in the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company’s stock valued at $22,165,000 after buying an additional 1,416,439 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of GH Research during the 1st quarter worth $5,018,000. RA Capital Management L.P. lifted its position in shares of GH Research by 3.9% during the 1st quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company’s stock worth $76,599,000 after purchasing an additional 257,959 shares during the last quarter. Troluce Capital Advisors LLC purchased a new stake in shares of GH Research during the 1st quarter worth $1,716,000. Finally, Walleye Capital LLC purchased a new stake in shares of GH Research during the 1st quarter worth $584,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

See Also

Earnings History and Estimates for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.